WO2023104148A1 - 结合α-突触核蛋白聚集体的小分子探针及其用途 - Google Patents

结合α-突触核蛋白聚集体的小分子探针及其用途 Download PDF

Info

Publication number
WO2023104148A1
WO2023104148A1 PCT/CN2022/137518 CN2022137518W WO2023104148A1 WO 2023104148 A1 WO2023104148 A1 WO 2023104148A1 CN 2022137518 W CN2022137518 W CN 2022137518W WO 2023104148 A1 WO2023104148 A1 WO 2023104148A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
synuclein
pharmaceutically acceptable
imaging
general formula
Prior art date
Application number
PCT/CN2022/137518
Other languages
English (en)
French (fr)
Inventor
楚勇
王坚
边江
刘逸奇
林欣
邱辰旸
何洁
叶德泳
Original Assignee
复旦大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 复旦大学 filed Critical 复旦大学
Publication of WO2023104148A1 publication Critical patent/WO2023104148A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6456—Spatial resolved fluorescence measurements; Imaging
    • G01N21/6458—Fluorescence microscopy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo

Definitions

  • the invention belongs to the technical field of medicine, and relates to a small molecule probe combined with ⁇ -synuclein aggregates and its application.
  • ⁇ -synuclein lesion is an important pathogenesis of neurodegenerative diseases (Vekrellis, 2010).
  • ⁇ -synuclein is an important pathological feature of Parkinson's disease (PD), Parkinsonian dementia (PDD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and various neurodegenerative disorders Abnormal aggregation of the lesion, and then the formation of Lewy bodies and Lewy neurites with Lewy bodies as the main components, leading to pathogenesis.
  • ⁇ -synuclein deposition The process from the formation of ⁇ -synuclein deposition to the appearance of clinical symptoms is relatively long, usually lasting several years or even more than ten years, and it is too late to intervene when the patient has already developed clinical symptoms.
  • Early clinical intervention is extremely important to delay the progression of the disease and improve the quality of life and prognosis of patients. Therefore, the development of reliable early detection methods is very important for the early diagnosis, prevention and treatment of neurodegenerative diseases.
  • regulating the aggregation process of ⁇ -synuclein is also an important strategy for the treatment of these neurological diseases.
  • ⁇ -synuclein Based on its important role in the pathogenesis and progression of the above-mentioned various neurodegenerative diseases, ⁇ -synuclein has become an important biomarker for early diagnosis of these diseases and an important target for drug treatment.
  • the current detection of ⁇ -synuclein aggregates can only be based on histological analysis of autopsy materials, and non-invasive detection of living bodies cannot be performed.
  • the use of molecular imaging is the best way to solve this problem.
  • Molecular imaging is based on the specific binding of molecular tracer probes (e.g. radioactive tracer probes, fluorescent tracer probes, etc.) to biomarkers (e.g. receptors, enzymes, ion channels, misfolded proteins), Then it is visualized and imaged by PET, SPECT, nuclear magnetic resonance, near-infrared or other methods to provide diagnostic information of the living body.
  • biomarkers e.g. receptors, enzymes, ion channels, misfolded proteins
  • the imaging probe of a specific protein not only needs to have a strong enough affinity for the target protein aggregate, It must also be sufficiently selective for abnormal accumulations of other proteins to enable selective imaging.
  • few small molecule tracer probes capable of imaging ⁇ -synuclein deposition in the brain of patients have been reported.
  • the purpose of the present invention is to provide a class of small molecule tracer probes capable of imaging ⁇ -synuclein aggregates, and small radionuclide-labeled probes for imaging diagnosis of ⁇ -synuclein accumulation diseases.
  • Molecular tracer probes, and preparation methods of these tracer probes in order to realize non-invasive early diagnosis, disease monitoring, and drug efficacy in vivo for patients with neurodegenerative diseases such as Parkinson's disease, Lewy body dementia, and multiple system atrophy Evaluate.
  • the present invention provides a compound represented by the following general formula I, a salt or a solvate thereof.
  • the compound has a strong affinity for ⁇ -synuclein aggregates, good selectivity for A ⁇ and Tau proteins, and good blood-brain barrier permeability, especially for good and specific binding and staining of patient brain
  • Lewy bodies and Lewy neurites in tissues can be used as fluorescent imaging tracers; or radioactively labeled as radiographic tracers required by imaging techniques such as PET and SPECT, for in vivo (such as in the brain) ⁇ - Imaging of synuclein pathology.
  • R 1 is a 5-6 membered heteroaryl group, preferably pyridyl
  • R 2 is selected from halogen group, nitro group, hydroxyl group, C 1-4 alkoxy group, halogenated C 1-4 alkoxy group, wherein the halogen atom
  • R 3 and R 4 are each independently selected from hydrogen, C 1-3 alkyl, preferably methyl;
  • Ring A is selected from benzene rings, 5- to 6-membered aromatic heterocycles, preferably from benzene rings and thiazole rings.
  • one or more atoms of the compound of formula I are radioactive isotopes of the atoms, and the radioactive isotopes are preferably
  • the present invention also provides the preparation method of formula I compound, and this method comprises following synthetic route:
  • the compound of formula a is ring-closed at room temperature to generate the compound of formula b.
  • the solvent used in the reaction includes but not limited to methanol, ethanol, dichloromethane, chloroform, triethylamine, dimethylformamide, tetrahydrofuran, dioxane.
  • the compound of formula b and the aldehyde of ring A are heated to generate the compound of formula c.
  • the solvent used is selected from methanol, ethanol, triethylamine, dimethylformamide, tetrahydrofuran, dioxane, acetic acid, methylene chloride, chloroform;
  • the acid used is selected from organic acids (including but not limited to oxalic acid, malic acid, tartaric acid) , citric acid, acetic acid) and inorganic acids (hydrochloric acid, sulfuric acid, nitric acid, trifluoroacetic acid);
  • the reaction temperature range is 20°C-150°C, and the preferred reaction temperature is 80°C-130°C.
  • the compound of formula c undergoes a nitrogen substitution reaction under the action of a base to obtain the compound of formula I.
  • the bases used include organic bases and inorganic bases, and the organic bases include but are not limited to sodium hexamethyldisilazide, triethylamine, N,N-diisopropylethylamine, n-butyllithium, tert-butyl Potassium alcoholate, tetrabutylammonium bromide, described inorganic bases include but not limited to sodium hydride, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or cesium carbonate; Solvent used is selected from dichloromethane, tetrahydrofuran, Dimethylsulfoxide, dioxane, dimethylformamide; the reaction can take place within the temperature range of 20-120°C, preferably the reaction temperature is 20°C-40°C.
  • the compound of formula I in which R2 is methoxy is demethylated to generate the compound of formula I in which R2 is hydroxyl, and the hydroxyl group is further subjected to oxyalkylation reaction to generate the compound of formula I in which R2 is haloalkoxy.
  • the present invention also provides a precursor compound for preparing the labeled compound of formula I, the structure of which is as follows:
  • R 5 is pyridyl
  • R 6 is independently selected from hydroxyl, fluorine, bromine, iodine, nitro, borate, TsO-(CH 2 )mO-, MsO-(CH 2 )mO-, wherein, m is an integer of 2-4.
  • One or more atoms in the compound of formula I can be labeled as a radionuclide by means of the aforementioned precursor compounds. Accordingly, the present invention also provides labeled compounds of formula I, preferably taken from the following structure:
  • the present invention also provides the use of the compound represented by formula I that can specifically bind to ⁇ -synuclein aggregates.
  • the compound has autofluorescence and can be used as a fluorescent imaging tracer; when one or more atoms in the compound are replaced by radioactive atoms, it can be used as a radioactive imaging tracer probe required by various imaging techniques, such as After one or more fluorine atoms or carbon atoms in the compound are replaced by radionuclide 18 F or 11 C, it can be used as a radioactive imaging tracer probe for PET imaging technology, or used to prepare the imaging tracer probe, and preparing a composition comprising the imaging tracer probe.
  • imaging tracers can be used to detect neurological diseases associated with ⁇ -synuclein misfolding and aggregation, or to screen for therapeutic or preventive drugs for diseases associated with ⁇ -synuclein aggregates in the brain, or It is used to quantify or determine the accumulation of ⁇ -synuclein aggregates in the brain.
  • PET Positron emission computed tomography
  • SPECT single photon emission computed tomography
  • the use of PET and SPECT radioactive tracer probes that specifically bind to a given molecular target can provide real-time diagnostic information that is closest to pathology in the living body, and prove and quantify the pathophysiological changes caused by the disease. It is an early clinical diagnosis and disease progression monitoring. and the most powerful tool for therapeutic drug development.
  • the radionuclides used in PET generally include 11 C, 13 N, 15 O, and 18 F, whose radioactive half-lives are 20 minutes, 10 minutes, 2 minutes, and 110 minutes, respectively.
  • 18 F has relatively the longest half-life and is the most convenient to use, 18 F is usually the best choice as the radionuclide for PET.
  • 99m Tc, 123 I, 131 I, 111 In are the most commonly used radionuclides for SPECT. In principle, these nuclides could be used to replace any corresponding non-radioactive isotopic atom in the target ligand molecule to render it radioactive for radioimaging.
  • the specific binding ligands of ⁇ -synuclein aggregates can be labeled and used as tracer probes for in vitro autoradiography and in vivo PET or SPECT imaging, realizing The pathological imaging of ⁇ -synuclein in vivo and in vitro has greatly promoted the diagnosis, management, mechanism research and development of therapeutic drugs for neurological diseases related to ⁇ -synuclein misfolding and aggregation.
  • the key to imaging is to find small ligand molecules with high affinity and high selectivity for ⁇ -synuclein, and further, to label them with radionuclides as imaging probes for PET and SPECT.
  • the present invention provides a class of compounds with strong affinity and high specificity for ⁇ -synuclein aggregates and can penetrate the blood-brain barrier.
  • These compounds are autofluorescent and highly specific for aggregated ⁇ -synuclein fibers in cell models, as well as Lewy bodies and Lewy neurites (which are primarily composed of ⁇ -synuclein aggregates) in patient brain tissue sexually binding and showing clear fluorescent staining, it can be used as a fluorescent imaging agent for ⁇ -synuclein.
  • radionuclide 18 F or 11 C When one or more fluorine atoms, or one or more carbon atoms in the compound of the present invention are replaced by radionuclide 18 F or 11 C, it can be used as an imaging tracer probe for autoradiography or PET Imaging of alpha-synuclein aggregates in vitro, in vivo, and especially in the brain.
  • the halogen atoms in the compounds of the present invention are replaced by radioactive isotopes or other nuclides, they can be used as tracking probes for SPECT to visualize ⁇ -synuclein aggregates.
  • the present invention also provides the preparation method of the compound of formula I and its radiolabeled compound, as well as the precursor compound used for preparing the radiolabeled compound and its preparation method. Further, an imaging diagnosis method of the compound of formula I or its composition, a drug screening method for preventing or treating ⁇ -synuclein accumulation diseases, and the accumulation of ⁇ -synuclein in the brain are also provided. A method of quantification or determination.
  • Fig. 1 is a laser confocal microscope photograph of the immunofluorescent staining results of the tracer probe of the present invention on ⁇ -synuclein aggregates in the SH-SY5Y cell model.
  • the white triangle indicates the signal of the compound co-localized with the ⁇ -synuclein antibody
  • the white arrow indicates the non-specific staining signal of the compound
  • the red arrow indicates the signal of the ⁇ -synuclein antibody that the compound failed to bind
  • the yellow arrow indicates Undissolved compound signal.
  • Fig. 2 is a fluorescent microscope photograph of the staining result of the tracer probe of the present invention on the brain slice of a patient with dementia with Lewy bodies (DLB).
  • white arrows indicate Lewy bodies (left image) or Lewy neurites (right image). This result shows that the tracer probe of the present invention can strongly bind to the ⁇ -synuclein aggregate lesion in the patient's brain.
  • Fig. 3 is a fluorescent microscope photograph of the staining result of the tracer probe of the present invention on brain slices of Alzheimer's (AD) patients.
  • the white arrows in the figure indicate A ⁇ primitive plaques, the white triangles indicate A ⁇ dense core plaques, and the yellow triangles indicate Tau neurofibrillary tangles. This result shows that the tracer probe of the present invention is weakly bound to A ⁇ and Tau lesions in the patient's brain, and has good tissue target selectivity.
  • ⁇ -synuclein accumulation disease refers to a disease in which ⁇ -synuclein is abnormally folded and accumulated in the brain, including but not limited to Parkinson's disease (PD), Parkinson's disease mental disorder (PDD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), etc.
  • PD Parkinson's disease
  • PPD Parkinson's disease mental disorder
  • MSA multiple system atrophy
  • DLB dementia with Lewy bodies
  • the present invention uses the compound of general formula I, its salt or its solvate as an imaging tracer probe to image ⁇ -synuclein in patients with ⁇ -synuclein accumulation disease in vivo and in vitro, so as to provide Diagnosis and evaluation information of these diseases.
  • the tracer probe that can be used for imaging diagnosis of ⁇ -synuclein accumulation disease in the present invention is the compound represented by general formula I, or its salt, or its solvate.
  • the compounds of the present invention have a double bond between the two rings, therefore the compounds of general formula I may have cis and trans isomers.
  • Preferred compounds are I-1, I-2, I-3, I-6, I-12, I-15.
  • I-15 can well label the ⁇ -synuclein lesion Lewy bodies and Lewy neurites in the brain tissue of dementia with Lewy bodies (DLB), and it has a good effect on the brain tissue of Alzheimer's patients (AD). A ⁇ lesions and Tau lesions showed low binding, showing good specificity.
  • the present invention also includes the salts of the compounds of general formula I.
  • the nitrogen atom in the compounds of general formula I can be used to form pharmaceutically acceptable salts.
  • any formula given herein is also intended to represent isotopically labeled forms of the compound. Its isotope-labeled compound has the structure shown in the chemical formula of formula I provided by the present invention, the difference is only that one or more atoms are replaced by its radioactive isotope.
  • Isotopes that may be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, chlorine and iodine such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, respectively , 35 S, 18 F, 36 Cl, 123 I and 125 I and 131 I.
  • Substitution with heavier isotopes may afford certain advantages resulting from greater metabolic stability (eg increased in vivo half-life or reduced dosage requirements).
  • Substitution with 2 H can be used in particular to prevent the formation of undesired radiometabolites or to block radiodefluorination.
  • 11 C, 13 N, 15 O, and 18 F are preferred for PET imaging among positron radioactive nuclides, 18 F is the most preferred, and 11 C is the second preferred labeling; Among the radionuclides, 123 I is preferred for SPECT imaging.
  • the present invention also encompasses radiolabeled compounds of general formula I.
  • any position of the compound of general formula I can be replaced by a radionuclide, but it is preferred to replace the halogen group, nitro group shown in the examples, or to label the alkyl group.
  • any position of the compound can be labeled with 18 F, preferably replacing the nitro group or fluorine atom in the compound with 18 F.
  • the radiolabeled compounds of the present invention and the precursor compounds required for their preparation can generally be prepared by conventional schemes, or the schemes disclosed in the examples, or the following methods (by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent) while preparing.
  • Many methods have been reported to label 11 C, 15 N, 18 O, 18 F or other isotopes into compounds (Angew. Chem. Int. Ed. Miller, Philip W, 2008, 47, 8998-9033; Peter JHScott, 2009, 48, 6001-6004; Chem. Rev., Sean Preshlock, 2016, 116, 719-766; Frederic Dollé, Fluorine-18chemistry for molecular imaging with positron emission tomography.
  • the compound of formula I labeled with a radionuclide can be used as a PET or SPECT tracer probe for imaging of ⁇ -synuclein accumulation in a living body.
  • the present invention also provides precursor compounds for the preparation of radionuclide-labeled compounds of formula I.
  • Those skilled in the art can design and synthesize the precursor compound according to the structure shown in the present invention. That is, the precursor compound can be obtained by structurally modifying a commercially available compound or the compound of the present invention.
  • the radiolabeled compounds of the invention can be prepared from different precursor compounds.
  • the labeling position of the precursor compound contains hydroxyl or nitro, bromine, iodine, borate or other easy-leaving groups (such as MsO-, TsO-, etc.), which can be labeled by 11 C or 18 F, respectively. .
  • the methoxy group contained in the compound of formula I of the present invention can be demethylated to obtain a precursor compound containing a hydroxyl group, and then labeled with 11 C; or with a brominated alkane that has been labeled with 18 F, such as 18 F-CH 2 CH 2 -Br undergoes oxyalkylation reaction to generate 18 F-CH 2 CH 2 -O-substitution product to realize radiolabelling.
  • the precursor compound may also contain bromine, iodine, borate or TsO-, MsO-, and these groups can be replaced by 18 F according to known conventional methods.
  • compounds that can be used to prepare radiotracer probes include I-5 (precursor to I-4 and I-6), I-8 (precursor to I-7 and I-9), I-11 (precursor to I-9), -10 and I-12 precursor), I-14 (I-13 and I-15 precursor) and so on.
  • I-5 precursor to I-4 and I-6
  • I-8 precursor to I-7 and I-9
  • I-11 precursor to I-9
  • -10 and I-12 precursor I-14 (I-13 and I-15 precursor) and so on.
  • the nuclide used for labeling is produced by a cyclotron, and those skilled in the art can select corresponding methods and instruments according to the nuclide to be produced. Methods for labeling compounds using these radionuclides are known in the art, mainly including chemical synthesis, isotope exchange and biosynthesis.
  • the radiolabeled compound of the present invention can be administered locally or systemically to the patient, and after a sufficient time of binding and dissociation with ⁇ -synuclein, the detection site can be visualized and imaged by PET or SPECT.
  • the route of administration can be subcutaneous, intraperitoneal, intravenous, arterial or intraspinal fluid injection or infusion, or oral, with due attention to the patient's exposure dose, and the specific use depends on the type of disease, the nuclide used, and the compound used , patient condition, detection site and other factors.
  • the present invention also provides a composition for imaging diagnosis of ⁇ -synuclein accumulation disease, which comprises the compound of the present invention, its pharmaceutically acceptable salt, or its solvate, and a pharmaceutically acceptable carrier.
  • a composition for imaging diagnosis of ⁇ -synuclein accumulation disease which comprises the compound of the present invention, its pharmaceutically acceptable salt, or its solvate, and a pharmaceutically acceptable carrier.
  • Compounds of the invention in preferred compositions are labeled, wherein labeling with radionuclides (especially positron-radiating nuclides 11 C, 13 N, 15 O, 18 F, etc.) is preferred for in vivo imaging diagnostics.
  • the compound of the present invention or a composition thereof is preferably in a form that allows injection.
  • pharmaceutically acceptable carriers are preferably liquids, including, but not limited to, aqueous solvents (such as potassium phosphate buffer, saline, Ringer's solution, and distilled water) or anhydrous solvents (such as polyethylene glycol, vegetable oils, ethanol , glycerin, dimethyl sulfoxide and propylene glycol).
  • aqueous solvents such as potassium phosphate buffer, saline, Ringer's solution, and distilled water
  • anhydrous solvents such as polyethylene glycol, vegetable oils, ethanol , glycerin, dimethyl sulfoxide and propylene glycol.
  • the formulation ratio of the carrier and the compound of the present invention can be appropriately selected, depending on the site of action, detection means, and the like.
  • composition of the present invention may contain commonly used antimicrobial agents (such as antibiotics, etc.), local anesthetics (such as procaine hydrochloride, tibucaine hydrochloride, etc.), buffers (such as trihydrochloride buffer, HEPES buffer, etc.) ), osmotic pressure regulators (such as glucose, sorbitol, sodium chloride, etc.), etc.
  • antimicrobial agents such as antibiotics, etc.
  • local anesthetics such as procaine hydrochloride, tibucaine hydrochloride, etc.
  • buffers such as trihydrochloride buffer, HEPES buffer, etc.
  • osmotic pressure regulators such as glucose, sorbitol, sodium chloride, etc.
  • Compounds of the invention may be labeled or unlabeled. When not labeled, the compound of the present invention can be labeled by the usual methods described above before use.
  • the compound of the present invention has the ability of highly specific binding to ⁇ -synuclein, so the labeled or unlabeled compound of the present invention can be used for staining and quantifying ⁇ -synuclein in vitro.
  • the compounds of the present invention have autofluorescent properties, they can be directly used to stain ⁇ -synuclein in specimens and observe through laser confocal or fluorescence microscopy, or to compare ⁇ -synuclein in samples. chromatographic quantification; or radiolabeled for quantification of ⁇ -synuclein using a scintillation counter.
  • the early pathological basis of synuclein diseases such as Parkinson's disease, Lewy body dementia, multiple system atrophy, etc. is the formation of Lewy bodies, the main component of which is abnormal accumulation of ⁇ -synuclein, and the detection of Lewy bodies can provide Early onset information for these diseases. Since the compound of the present invention can clearly stain Lewy bodies and Lewy neurites, it can be used for research on relevant pathological mechanisms and diagnosis before and after death of patients. Staining of brain sections with the compound of the present invention can be carried out by common methods.
  • the compound of the present invention that is, the compound represented by the general formula I or its salt or its solvate can be used as an imaging probe for ⁇ -synuclein accumulation, preferably using a radionuclide-labeled imaging probe. Needle.
  • the present invention provides:
  • Optical and radioactive tracer probes for imaging diagnosis of ⁇ -synuclein accumulation diseases especially imaging tracer probes labeled with positron radionuclides;
  • a composition for imaging and diagnosing ⁇ -synuclein accumulation diseases which comprises a compound of general formula I, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier;
  • the present invention also provides:
  • a method for quantifying or determining the accumulation of ⁇ -synuclein in the brain a method for screening drugs for the prevention and/or treatment of ⁇ -synuclein accumulation diseases;
  • the above-mentioned methods all include using the compound of general formula I, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • compound of formula I refers to any compound selected from the class of compounds defined by formula I, including stereoisomers, cis Transisomers, tautomers, solvates and salts (eg pharmaceutically acceptable salts).
  • the term "one or more" means from one substituent to the largest chemically possible number of substitution, ie replacement of one hydrogen to replacement of all hydrogens by a substituent.
  • substituted refers to an atom or group of atoms that replaces a hydrogen atom on a parent molecule.
  • halogen refers to fluorine (-F), chlorine (-Cl), bromine (-Br), and iodine (-I).
  • TsO- means "MsO-" means
  • C 1-4 alkoxy refers to a group of formula -O-R', wherein R' refers to a monovalent linear or branched saturated alkyl group containing 1 to 4 carbon atoms. Examples thereof include methoxy.
  • halogenated C 1-4 alkoxy denotes an alkoxy group in which one or more hydrogen atoms of the alkoxy group have been replaced by the same or different halogen atoms (especially fluorine atoms). Examples thereof include 1-fluoroethoxy.
  • C 1-3 alkyl means a monovalent linear or branched saturated hydrocarbon group of 1 to 3 carbon atoms. Examples thereof include methyl.
  • 5-6 membered aromatic heterocyclic ring means an aromatic monocyclic heterocyclic ring of 5 or 6 ring atoms, which contains 1, 2, 3 or 4 heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Examples thereof include thiophene rings.
  • aromatic denotes the conventional concept of aromaticity as defined eg in the literature (in particular IUPAC - Catalog of Chemical Terms 2nd Edition, A.D. McNaught & A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)).
  • pharmaceutically acceptable salt refers to a salt that is not harmful to mammals, especially to humans.
  • Pharmaceutically acceptable salts may be formed using non-toxic acids or bases comprising inorganic acids or bases, or organic acids or bases.
  • Pharmaceutically acceptable salts include, for example, metal salts formed with aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc; Organic salts formed by caine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine, etc.
  • the pharmaceutically acceptable salts include acid addition salts and base addition salts.
  • pharmaceutically acceptable carrier refers to physiological saline solution; liquid or solid fillers, diluents, solvents, or packaging materials that are pharmaceutically acceptable materials, compositions, or excipients.
  • Pharmaceutically acceptable carriers include, but are not limited to: water, saline, normal saline or phosphate-buffered saline (PBS), sodium chloride injection, Ringer's injection, glucose injection, sterile water injection, Glucose, and Lactated Ringer's Injection, etc.
  • solvate refers to a solvent-containing compound formed by the association of one or more solvent molecules with a compound.
  • monosolvates, disolvates, trisolvates, and tetrasolvates may be included.
  • solvates also include hydrates.
  • hydrate refers to a compound or a salt thereof containing water bound by non-covalent intermolecular forces, and the amount of water contained may be stoichiometric or non-stoichiometric. For example, monohydrate, dihydrate, trihydrate, and tetrahydrate etc. are contained.
  • tracer probe (hereinafter, also referred to as tracer probe) of ⁇ -synuclein aggregate provided by the present invention, namely the compound shown in the following formula I, its pharmaceutically acceptable salt, or its solvent compounds.
  • the compound represented by the following formula I has autofluorescence.
  • one or more atoms of the compound may be radioactive isotopes of the atoms. Therefore, the compound of the present invention can be used as a small molecule tracking probe for optical imaging of ⁇ -synuclein aggregates, or PET and SPECT imaging after radiolabeling.
  • R 1 is a 5-6 membered heteroaryl group, preferably pyridyl
  • R 2 is selected from halogen group, nitro group, hydroxyl group, C 1-4 alkoxy group, halogenated C 1-4 alkoxy group, and the halogen atom is selected from fluorine, chlorine, bromine or iodine;
  • R 3 and R 4 are each independently selected from hydrogen, C 1-3 alkyl, preferably methyl;
  • Ring A is selected from benzene rings, 5- to 6-membered aromatic heterocycles, preferably from benzene rings and thiazole rings.
  • one or more atoms of the compound of formula I are radioactive isotopes of the atoms, and the radioactive isotopes are preferably taken from 11 C, 13 N, 15 O, 18 F, 76 Br, 123 I, 125 I, 131 I.
  • the atoms marked with * in the above specific compound structural formula may be the radioactive isotope of the atom, such as 11 C or 18 F.
  • F in the specific compounds above is the radioisotope18F ; preferably, the carbon atom of the methoxy or dimethylamino group linked to the aryl group is the radioisotope11C .
  • composition for optical imaging of ⁇ -synuclein aggregates of the present invention comprises the compound of formula I above, its pharmaceutically acceptable salt, or its solvate.
  • the optical imaging includes in vitro imaging, in vitro imaging, and in vivo imaging.
  • the optical imaging methods include, but are not limited to, fluorescence microscopy, multiphoton imaging, two-photon imaging, and near-infrared fluorescence imaging.
  • composition for radiographic imaging of ⁇ -synuclein aggregates of the present invention comprises a radiolabeled compound of formula I, a pharmaceutically acceptable salt thereof, or a solvent thereof compounds.
  • the radiographic imaging includes in vitro imaging, in vitro imaging, and in vivo imaging.
  • the radiographic methods include, but are not limited to, PET, SPECT, autoradiography.
  • compositions for optical imaging and the composition for radiographic imaging can be contained in the aforementioned pharmaceutically acceptable carrier.
  • the content of the compound of formula I contained therein, its pharmaceutically acceptable salt, or its solvate, and the pharmaceutically acceptable carrier are not particularly limited, and can be determined according to: the compound used; the mammal to be administered The age, weight, health status, gender and meal content of the patient; the frequency and route of administration; the treatment period; other drugs used at the same time should be adjusted.
  • the diagnostic drug of the ⁇ -synuclein aggregate-related disease of the present invention, or the companion diagnostic drug for the treatment or prevention of the disease includes the compound of the present invention.
  • the therapeutic accompanying diagnostic drug refers to a diagnostic drug used to judge whether or not treatment is expected when the above-mentioned disease is identified.
  • the prophylactic companion diagnostic drug refers to a diagnostic drug for predicting future onset or for judging whether preventive onset suppression is expected when the precursor symptoms of the above-mentioned disease are known.
  • the relevant data on the amount and/or distribution of ⁇ -synuclein aggregates in the subject obtained by using the above-mentioned diagnostic drugs or companion diagnostic drugs, and the previously known relationship between the above-mentioned diseases and ⁇ -synuclein
  • the subject can be diagnosed with the above-mentioned diseases (specifically, such as whether he suffers from the above-mentioned diseases, severity, possibility of attack, etc.) ); or understand the above-mentioned disease state of the subject, and based on this, formulate a prevention/treatment plan for the above-mentioned disease (types of preventive administration/treatment drugs and their combinations, dosage, usage, etc.).
  • the optical imaging method of the present invention includes the following steps.
  • the method for detecting ⁇ -synuclein aggregates in the brain is used as an example for illustration, and the method for detecting other parts is similar.
  • the tracer probe of the present invention When an effective amount of the tracer probe of the present invention is administered to a test organism, the tracer probe that reaches the brain of the organism will bind to ⁇ -synuclein aggregates in the brain. Then, the light of the first wavelength for exciting the tracer probe is irradiated from outside the brain, and the light of the second wavelength (such as fluorescence) emitted from the tracer probe in the brain is detected, thereby achieving detection of ⁇ -synuclein aggregates Optical imaging (picture).
  • the tracer probe comprises a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
  • the radiation imaging method of the present invention includes the following steps, which are illustrated below by using the method for detecting ⁇ -synuclein aggregates in the brain, and the method for detecting other parts is similar.
  • the tracking probe When an effective amount of the radiolabeled tracking probe of the present invention is administered to a test organism, the tracking probe that reaches the brain of the organism will bind to ⁇ -synuclein aggregates in the brain. Radiation emitted from the tracer probe in the brain is then detected to realize radiographic imaging (imaging) of ⁇ -synuclein aggregates.
  • the tracer probe comprises a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein one or more atoms of the compound of formula I are radioactive isotopes of the atom.
  • optical imaging and radioimaging test organisms include mammals, such as human, rat, mouse, rabbit, guinea pig, hamster, monkey, dog, mink, or miniature pig.
  • the mammal is a human.
  • the administration method of the tracer probe is not particularly limited, and it can be administered orally, intravenously or intraperitoneally. Intravenous or intraperitoneal injection is preferred, and intravenous injection is most preferred.
  • the accumulation of synuclein is quantified and the presence or absence of accumulation of alpha-synuclein aggregates in vivo (eg, in the brain) is determined.
  • the screening drug Based on the imaging method described in [Optical Imaging Method] or [Radiographic Imaging Method] above, detect the light or radiation emitted by the test organism before and after administration of the screening drug, and judge according to the difference in intensity and/or distribution Changes in alpha-synuclein accumulation to screen for therapeutic or preventive drugs. For example, after administration of a screening drug, if the amount (intensity) of light (such as fluorescence) or radiation from the tracer probe is reduced compared to before administration of the screening drug, the screening drug may be used as a drug for the treatment or prevention of the disease or condition .
  • the The screened drug may be used as a treatment or preventive drug for the disease or condition.
  • test organism The species of the test organism and the method of administration are the same as described above in [Optical Imaging Method] and [Radiographic Imaging Method].
  • the compound of the present invention can be synthesized from known materials (for example, commercially available materials) by known methods. Those skilled in the art can appropriately select starting materials and synthesis methods according to the desired compound of the present invention. The present invention will be further described below in conjunction with the examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the protection scope of the present invention. For the experimental methods that do not indicate specific conditions in the following examples, conventional conditions or the conditions suggested by the manufacturer are usually adopted.
  • the known starting materials of the present invention can be used or prepared according to methods known in the art, or purchased from commercial products. Compound structures were determined by nuclear magnetic resonance spectroscopy (NMR) and/or mass spectroscopy.
  • Embodiment 1 The preparation of compound I-1 is as follows:
  • Step b Preparation of intermediate c-1
  • Embodiment 2 the preparation of compound 1-2, its structure is as follows:
  • Embodiment 3 the preparation of compound I-3, its structure is as follows:
  • Embodiment 4 the preparation of compound 1-4, as follows:
  • Embodiment 5 the preparation of compound 1-6, as follows:
  • Embodiment 6 the preparation of compound I-9, as follows:
  • the preparation method of I-7 is the same as compound I-4, except that 2-bromomethylpyridine is replaced by 3-bromomethylpyridine.
  • the preparation method of subsequent steps is the same as I-6.
  • a brick red solid was obtained in 12% yield.
  • ESI-MS positive): 445.2 (M+1) + .
  • Embodiment 7 the preparation of compound I-12, as follows:
  • the preparation method of I-10 is the same as compound I-4, except that 2-bromomethylpyridine is replaced by 4-bromomethylpyridine.
  • the preparation method of subsequent steps is the same as I-6.
  • a brick red solid was obtained in 14% yield.
  • Embodiment 8 the preparation of compound I-15, as follows:
  • the preparation method of I-13 is the same as that of I-4, except that 4-dimethylaminobenzaldehyde is replaced by 2-dimethylaminothiazole-5-carbaldehyde in step e, and the subsequent steps are the same as the preparation method of I-6.
  • a red solid was obtained in 21% yield.
  • Labeling of various radionuclides can be performed by conventionally known methods. The following uses the preparation of ( 18 F)I-1, ( 18 F)I-15 and ( 11 C)I-13 as an example to illustrate the methods of labeling 18 F and 11 C respectively. Other radioactive tracer probes can be prepared in the same manner. Method preparation.
  • a number of different precursor compounds can be labeled with radionuclide 18 F.
  • the synthesis methods of three precursor compounds are exemplified below, but not limited thereto.
  • Example 1 4-fluoro-o-phenylenediamine was replaced by 4-nitro-o-phenylenediamine and 4-bromo-o-phenylenediamine respectively to prepare nitro-containing precursor compound I-1N and the bromine-containing precursor compound I-1B. Further, the bromine-containing precursor I-1B was coupled with pinacol borate under palladium catalysis to prepare the more active boronate-containing precursor compound I-1O. All the above three precursor compounds can react with radioactive K 18 F to generate radioactive tracer probe ( 18 F)I-1.
  • Method 1 Synthesis from borate-containing precursor compound I-1O. 18 F- is produced by a cyclotron, then adsorbed by QMA, and the K 222 /K 2 CO 3 eluent is extruded from the No. 1 bottle to elute 18 F ions into the reaction tube, and evaporated to dryness at 116°C under nitrogen flow.
  • the No. 2 bottle solution (2 mL of acetonitrile) was injected into the reaction tube, and the water was removed by azeotropic evaporation at 116° C. under nitrogen flow. The reaction tube was cooled for 60 s. The No.
  • Method 2 Synthesis from nitro-containing precursor compound I-1N.
  • ( 18 F) Fluoride ions were dissolved in a 50% acetonitrile solution (0.4 mL) containing K 222 (Kryptofix222) (7.5 mg) and potassium carbonate (2.77 mg), and the solution was introduced into the reaction vessel, followed by Heating under a stream of nitrogen allowed the solvent to dry and solidify. Then, anhydrous acetonitrile (0.1 mL) was added for azeotropic distillation, and the inside of the reaction vessel was sufficiently dried. A solution of nitro group-containing precursor compound I-1N (1 mg) in DMSO (300 ⁇ L) was added to the reaction vessel, followed by heating at 110° C. for 10 minutes. After cooling, it was separated and purified by HPLC to obtain the pure product of ( 18 F)I-1.
  • bromine-containing precursor compound I-1B can also be labeled with 18 F under the conditions similar to the method 2 above to synthesize ( 18 F)I-1.
  • the radioactive tracer probe ( 18 F)I-15 can be directly oxyalkylated with its precursor compound I-14 and bromoalkane 18 F-CH 2 CH 2 -Br that has been labeled with 18 F preparation. Or react I-14 with 1,2-bis(toluenesulfonyloxy)ethane to generate the precursor compound I-15T containing leaving group TsO-; also react I-14 with ethylene oxide to generate Compound I-15O containing a terminal hydroxyl group is then reacted with p-toluenesulfonyl chloride (TsCl) or methanesulfonyl chloride (MsCl) under basic conditions to generate a labeling site containing an easily leaving group (such as TsO- or MsO-) precursor compound (such as I-15T); finally react I-15T with radioactive K 18 F to generate radioactive tracer probe ( 18 F)I-15.
  • TsCl p-toluenesulfonyl chloride
  • Example 11 Synthesis of radioactive tracer probe ( 11 C)I-13, as shown in the figure below, the synthesis needs to be protected from light.
  • Iodo( 11 C)methane was added to a solution of I-14 (2 mg) in dimethylsulfoxide (DMSO) (300 ⁇ L) at room temperature.
  • DMSO dimethylsulfoxide
  • the reaction mixture was heated at 120°C for 5 minutes.
  • the ( 11 C)I-13 fraction was recovered in a flask containing ethanol (300 ⁇ L), 25% ascorbic acid (100 ⁇ L) and Tween80 (75 ⁇ L), and the solvent was distilled off under reduced pressure. The residue was dissolved in physiological saline (3 mL, pH 7.4) to obtain ( 11 C)I-13 as an injection solution.
  • the binding activity of the compounds of the present invention to human ⁇ -synuclein aggregates was determined by the fluorescence method described below.
  • Bacteria were collected by centrifugation, ultrasonically crushed and then centrifuged at high speed for 30 minutes, the supernatant was collected, DNA and foreign proteins were removed by Ni-NTA affinity column chromatography, and then purified by molecular exclusion chromatography to obtain ⁇ -synuclein monomer. Purity was verified by SDS-PAGE discontinuous electrophoresis.
  • ⁇ -synuclein monomer into a Buffer solution containing 1 ⁇ PBS, in which the final protein concentration is 100 ⁇ M (about 5 mg/mL), and incubate at 37°C in a 1000 rpm shaker for 7 days to obtain ⁇ -synuclein Aggregates. Both initial protein monomer concentration and final concentration were accurately determined by BCA method.
  • the prepared ⁇ -synuclein aggregates are also called preformed fibers (preformed fibrils, PFFs), which are used for protein affinity testing, cell model construction and testing described in the present invention.
  • Example compound Kd ( ⁇ M) Example compound Kd ( ⁇ M)
  • Example compound Kd ( ⁇ M) Example compound Kd ( ⁇ M)
  • Example compound Kd ( ⁇ M) I-1 *** I-6 ** I-15 *** I-2 * I-9 * the the I-3 * I-12 ** the the
  • SH-SY5Y cells belong to the SK-N-SH cell line, which is a kind of human neuroblastoma cells.
  • the cells can express a variety of important neuronal proteins, such as dopaminergic transporters, dopamine hydroxylase, tyrosine hydroxylase, etc., so they are often used to study the mechanism of Parkinson's disease and evaluate drug efficacy.
  • the prepared ⁇ -synuclein aggregates PFFs
  • the model cells were incubated with ⁇ -synuclein antibody and compound respectively, washed with PBS and observed under a microscope.
  • the specific operation is as follows.
  • SH-SY5Y cells were cultured in high-glucose DMEM medium (containing 10% Gibco fetal bovine serum). After being resuscitated and passaged for 5 times, the cell state tended to be stable, and then PFFs were added to the medium, and fluorescent staining was performed after 48 hours of culture. experiment.
  • the brain slices of a patient with dementia with Lewy bodies were obtained from the amygdala tissue of a 75-year-old male deceased who suffered from stage 2 dementia with Lewy bodies. Cryosections of amygdala tissues enriched in ⁇ -synuclein lesions were performed at a thickness of 20 ⁇ m.
  • AD Alzheimer's Patients
  • Alzheimer's patient brain slices were obtained from the postmortem superior temporal gyrus of a stage 3 patient.
  • the dewaxed brain tissue was fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned with a thickness of 6 ⁇ m.
  • the detection method is the same as the above-mentioned staining method for the brain slices of patients with dementia with Lewy bodies (DLB).
  • the results of fluorescence images are shown in Figure 3.
  • Compound I-15 can also detect A ⁇ primitive plaques, A ⁇ dense core plaques, and Tau neurofibrillary tangles in brain slices of AD patients, but does not combine with Tau neurofibrillary filaments.
  • the staining signal of the compound is much weaker than that of DLB patient brain slices, indicating that I-15 binds weakly to A ⁇ and Tau pathological tissues.
  • the compound of the present invention was injected into the tail vein of rats to measure the blood-brain barrier permeability in vivo.
  • the blood taken out was centrifuged at 9000rpm for 5min, 200 ⁇ L of supernatant was taken, 800 ⁇ L of methanol was added, centrifuged at 14000rpm for 10min, the supernatant was passed through a 0.22 ⁇ m filter membrane, and stored at -80°C for later use.
  • LC-MS/MS was used to detect the concentration of the compounds in the blood sample and the brain homogenate supernatant sample respectively.
  • the brain/blood ratio is ⁇ 0.1, 0.1-0.3 or >0.3, it means that the degree of penetration of the compound through the blood-brain barrier is difficult, moderate or good, respectively.
  • the test results show that the brain/blood ratio of compounds I-6, I-12 and I-15 of the present invention is close to 1.0 or greater than 1.0, which proves that they all have good blood-brain barrier penetration ability. Since the compounds of the present invention are similar in structure, and the clogP values are mostly between 1.0 and 3.0, it can be predicted that other compounds of the present invention should also have acceptable blood-brain barrier penetration ability.
  • the probe compound capable of binding/staining ⁇ -synuclein aggregates and its composition of the present invention are extremely important for the early detection, treatment and prevention of difficult diseases such as Parkinson's disease, one of the current very important medical difficulties, And it has a very high possibility of being used in the medical field.
  • the compound of the present invention can be used as an imaging tracer for imaging the accumulation of ⁇ -synuclein, thereby being able to treat various neurodegenerative diseases, such as Parkinson's disease (PD), Parkinson's disease dementia (PDD) ), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), etc. provide information on early diagnosis and disease progression.
  • PD Parkinson's disease
  • PDD Parkinson's disease dementia
  • DLB dementia with Lewy bodies
  • MSA multiple system atrophy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明公开了如下通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其中，R1优选为吡啶基；R2优选为卤素基、卤代的C1-4烷氧基；R3、R4优选为甲基；环A优选为苯环、噻唑环。本发明化合物能特异性地强结合α-突触核蛋白聚集体，可作为α-突触核蛋白聚集体的小分子探针，用于生物样本或生物体内(如脑)中的α-突触核蛋白聚集体的光学显像；其放射标记物可用作PET、SPECT等影像检查技术所用的显像示踪探针，实现对活体内(如脑)的α-突触核蛋白病变的非侵入性的成像可视化检测。本发明化合物还用于制备上述放射标记的显像示踪探针或其组合物。所述α-突触核蛋白病变的疾病包括帕金森病、帕金森病性失智症、阿尔茨海默症、多系统萎缩、路易体痴呆症等。

Description

结合α-突触核蛋白聚集体的小分子探针及其用途 技术领域
本发明属于医药技术领域，涉及结合α-突触核蛋白聚集体的小分子探针及其用途。
背景技术
α-突触核蛋白(α-synuclein,α-Syn)病变是神经变性疾病的重要发病机制(Vekrellis，2010)。帕金森病(PD)、帕金森病性失智症(PDD)、路易体痴呆症(DLB)、多系统萎缩(MSA)及多种神经变性病症的重要病理特征均为α-突触核蛋白的异常聚集，进而形成以其为主要成分的路易体和路易神经突并导致发病。从α-突触核蛋白沉积形成到出现临床症状的过程较为漫长，通常持续数年甚至十年以上，而当病人已经出现临床症状时再行干预则为时已晚。越早的临床干预对延缓病程进展、改善患者的生活质量和预后都极为重要。因此，发展可靠的早期检测方法对神经变性疾病的早期诊断、预防和治疗十分重要。同时，调节α-突触核蛋白的聚集进程也是治疗这些神经疾病的重要策略。
基于在上述多种神经退行性疾病发病及病程进展中的重要作用，α-突触核蛋白已成为针对这些疾病进行早期诊断的重要生物标志物和药物治疗的重要靶点。但目前对α-突触核蛋白聚集体的检测只能基于尸检材料的组织学分析，还不能针对活体进行非侵入性的检测，运用分子影像学是解决这一难题的最佳方法。
分子影像学是基于分子示踪探针(例如放射性示踪探针、荧光示踪探针等)对生物标志物(例如，受体、酶、离子通道、错误折叠的蛋白质)的特异性结合，再通过PET、SPECT、核磁共振、近红外或其他方法对其进行可视化成像，从而提供活体的诊断信息。要实现分子影像其关键是必须具有能对给定分子靶标特异结合的小分子化合物作为显像示踪探针。由于神经退行性病人脑中常常共沉积α-突触核蛋白、Aβ和Tau蛋白的病理改变，因此，某一特定蛋白的显像探针不仅需要对该靶蛋白聚集体有足够强的亲和力，还必须对其他蛋白的异常积聚体具有足够高的选择性，才能实现选择性成像。迄今为止，鲜见报道能显像病人脑内α-突触核蛋白沉积的小分子示踪探针。
发明的公开
本发明的目的是提供一类能够显像α-突触核蛋白聚集体的小分子示踪探针、以及用于α-突触核蛋白积聚性疾病的成像诊断的被放射核素标记的小分子示踪探针，以及这些示踪探针的制备方法，以实现对帕金森病、路易体痴呆症、多系统萎缩等神经退行性疾病患者活体非侵入性的早期诊断、疾病监测和药物疗效评估。
为达到上述目的，本发明提供了如下通式I所示的化合物、其盐或其溶剂化物。该化合物对α-突触核蛋白聚集体具有强亲和力，且对Aβ和Tau蛋白具有良好的选择性，并具有良好的血脑屏障透过性，尤其能良好且特异性地结合并染色病人脑组织中的路易体和路易神经突，可用作荧光成像示踪剂；或经放射标记后用作PET、SPECT等影像技术所需的放射显像示踪剂，对体内(如脑中)α-突触核蛋白病理进行成像。
Figure PCTCN2022137518-appb-000001
其中，
R 1为5～6元芳杂基，优选地取为吡啶基；
R 2选自卤素基、硝基、羟基、C 1-4烷氧基、卤代的C 1-4烷氧基，其中，所述的卤素原子
选自氟、氯、溴或碘；
R 3、R 4各自独立地选自氢，C 1-3烷基，优选地取自甲基；
环A选自苯环、5～6元芳杂环，优选地取自苯环、噻唑环。
其中，式I化合物的1个或1个以上原子是该原子的放射性同位素，该放射性同位素优
选取自 11C、 13N、 15O、 18F、 76Br、 123I、 125I、 131I。
本发明还提供了式I化合物的制备方法，该方法包括以下合成路线：
Figure PCTCN2022137518-appb-000002
式a化合物在室温条件下关环生成式b化合物。反应所用溶剂包括但不限于甲醇、乙醇、二氯甲烷、氯仿、三乙胺、二甲基甲酰胺、四氢呋喃、二氧六环。酸性条件下，并以浓硫酸为催化剂，式b化合物与环A的醛加热生成式c化合物。所用溶剂选自甲醇、乙醇、三乙胺、二甲基甲酰胺、四氢呋喃、二氧六环、醋酸、二氯甲烷、氯仿；所用酸选自有机酸(包括但不限于草酸、苹果酸、酒石酸、柠檬酸、乙酸)和无机酸(盐酸、硫酸、硝酸、三氟乙酸)；反应温度范围为20℃-150℃，优选反应温度为80℃-130℃。式c化合物在碱的作用下进行氮取代反应得到式I化合物。所用碱包括有机碱和无机碱，所述的有机碱类包括但不限于六甲基二硅基氨基钠、三乙胺、N,N-二异丙基乙胺、正丁基锂、叔丁醇钾，四丁基溴化铵，所述的无机碱类包括但不限于氢化钠、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾或碳酸铯；所用溶剂选自二氯甲烷、四氢呋喃、二甲亚砜、二氧六环、二甲基甲酰胺；反应可在20-120℃温度范围内发生，优选反应温度为20℃-40℃。
进一步地，R 2为甲氧基的式I化合物脱除甲基生成R 2为羟基的式I化合物，该羟基进一步进行氧烷基化反应，生成R 2为卤代烷氧基的式I化合物。
本发明还提供了用于制备被标记的式I化合物的前体化合物，其结构如下所示：
Figure PCTCN2022137518-appb-000003
其中，R 5为吡啶基；R 6独立地取自羟基、氟、溴、碘、硝基、硼酸酯基、TsO-(CH 2)m-O-、MsO-(CH 2)m-O-，其中，m为2～4的整数。
通过上述前体化合物，可将式I化合物中的1个或多个原子标记为放射性核素。因此，本发明还提供了被标记的式I化合物，优选地取自如下结构：
Figure PCTCN2022137518-appb-000004
其中，具有*的原子中至少有一个是该原子的放射性同位素。
本发明还提供了式I所示能特异性结合α-突触核蛋白聚集体的化合物的用途。该化合物具有自发荧光，可用作荧光显像示踪剂；当该化合物中1个或多个原子被放射性原子取代后可用作多种影像技术所需的放射性显像示踪探针，例如该化合物中1个或多个氟原子或碳原子被取代为放射性核素 18F或 11C后，可用作PET影像技术的放射性显像示踪探针，或用于制备该显像示踪探针，以及制备包括该显像示踪探针的组合物。这些显像示踪剂可用于检测与α-突触核蛋白错误折叠和聚集相关的神经疾病、或用于筛选与脑内α-突触核蛋白聚集体相关的疾病的治疗或预防药物，或用于对脑内α-突触核蛋白聚集体的积聚进行定量或判定。
本发明的有益效果
正电子发射计算机断层显像(PET)和单光子发射计算机断层显像(SPECT)技术是当前最先进的非侵入性的三维显像技术。运用对给定分子靶标特异结合的PET、SPECT放射性示踪探针，能够实时提供活体最接近于病理学的诊断信息，证明和量化由于疾病产生的病理生理变化，是临床早期诊断，疾病进展监测及治疗药物开发的最有力工具。用于PET的放射性核素通常包括 11C、 13N、 15O和 18F，其放射性半衰期分别为20分钟、10分钟、2分钟和110分钟。由于 18F具有相对最长的半衰期，使用最为方便，故通常最优选择 18F作为PET的放射核素。此外， 99mTc, 123I, 131I, 111In是最常用于SPECT的放射核素。原则上，可以使用这些核素 替换靶标配体分子中的任一对应的非放射性同位素原子，以使其具有放射性用于放射成像。
因此，当标记上放射性核素后，α-突触核蛋白聚集体的特异结合配体就可以对其进行标记，用作体外放射自显影和体内PET或SPECT显像的示踪探针，实现体内外α-突触核蛋白的病理学成像，极大促进对α-突触核蛋白错误折叠和聚集相关的神经病症的诊断、管理、机制研究和治疗药物的发展。显然，实现显像的关键在于发现对α-突触核蛋白具有高亲和力和高选择性的配体小分子，进一步地，将其标记上放射核素作为PET、SPECT的显像探针。本发明提供了一类对α-突触核蛋白聚集体具有强亲和力和高度特异性、并能透过血脑屏障的化合物。这些化合物具有自发荧光，能对细胞模型中聚集的α-突触核蛋白纤维，以及病人脑组织中的路易体和路易神经突(其主要成分为α-突触核蛋白聚集体)发生高度特异性结合并显示出清晰的荧光染色，可用作α-突触核蛋白的荧光成像显像剂。当将本发明化合物中的1个或多个氟原子、或1个或多个碳原子替换为放射性核素 18F或 11C，可用作放射自显影或PET的显像示踪探针进行体外、体内(尤其是脑中)α-突触核蛋白聚集体的成像。当将本发明化合物中的卤素原子替换为放射性的同位素或其他核素时，可用作SPECT的示踪探针以显像α-突触核蛋白聚集体。
本发明还提供了式I化合物及其放射标记化合物的制备方法，以及用于制备放射标记化合物的前体化合物及其制备方法。进一步地，还提供了式I化合物或其组合物的成像诊断方法、用于预防或治疗α-突触核蛋白积聚性疾病的药物的筛选方法，及对脑内α-突触核蛋白的积聚进行定量或判定的方法。
附图的简要说明
图1为本发明示踪探针对SH-SY5Y细胞模型中α-突触核蛋白聚集体的免疫荧光染色结果的激光共聚焦显微镜拍照。图中，白色三角表示与α-突触核蛋白抗体共定位的化合物信号，白色箭头表示化合物的非特异性染色信号，红色箭头表示化合物未能结合的α-突触核蛋白抗体信号，黄色箭头表示未能溶解的化合物信号。
图2为本发明示踪探针对路易体痴呆症(DLB)病人脑片的染色结果的荧光显微镜拍照。图中，白色箭头表示路易体(左图)或路易神经突(右图)。该结果表明本发明示踪探针能与病人脑中的α-突触核蛋白聚集体病变发生强结合。
图3为本发明示踪探针对阿尔茨海默(AD)病人脑片的染色结果荧光显微镜拍照。图中白色箭头表示Aβ原始斑块，白色三角表示Aβ致密核心斑块，黄色三角表示Tau神经纤维缠结。该结果表明本发明示踪探针对病人脑中的Aβ和Tau病变结合很弱，具有良好的组织靶标选择性。
实现本发明的最佳方式
在本说明书中，“α-突触核蛋白积聚性疾病”是指α-突触核蛋白在大脑内异常折叠和积聚的疾病，包括但不限于帕金森病(PD)、帕金森病性失智症(PDD)、多系统萎缩(MSA)、路易体痴呆症(DLB)等。本发明通过在α-突触核蛋白积聚性疾病患者体内外使用通式I化合物、其盐或其溶剂化物，作为显像示踪探针对α-突触核蛋白进行显像，以提供对这些疾病的诊断、评估信息。
本发明可被用作成像诊断α-突触核蛋白积聚性疾病的示踪探针是通式I所示的化合物，或其盐，或其溶剂化物。本发明化合物在两个环之间具有双键，因此通式I化合物可以具有顺式和反式异构体。优选的化合物为I-1、I-2、I-3、I-6、I-12、I-15。其中，尤其是I-15能良好标记路易体痴呆症病人(DLB)脑组织中的α-突触核蛋白病变路易体和路易神经突，且对阿尔茨海默病人(AD)脑组织中的Aβ病变和Tau病变显示出低的结合，表现出了良好的特异性。
本发明还包括通式I化合物的盐。通式I化合物中的氮原子可用于形成医药上可接受的 盐。
本发明给出的任何化学式还旨在表示该化合物的同位素标记的形式。其同位素标记化合物具有由本发明给出的式I化学式所示结构，不同之处仅为其中的一个或多个原子被其放射性同位素替代。可以掺入本发明化合物的同位素包括氢、碳、氮、氧、氟、氯和碘的同位素，分别诸如 2H、 3H、 11C、 13C、 14C、 15N、 18O、 17O、 35S、 18F、 36Cl、 123I和 125I和 131I。用较重的同位素(诸如氘， 2H))取代可以提供某些由更大的代谢稳定性(例如增加的体内半衰期或降低的剂量需求)产生的优势。用 2H取代可以特别地用于防止形成不希望的放射代谢物或者阻断放射脱氟。用于标记本发明化合物时，在正电子放射性核素中优选 11C、 13N、 15O、 18F用于PET显像，最优选使用 18F，次优选使用 11C进行标记；在γ射线放射性核素中优选 123I用于SPECT显像。
本发明还包含通式I的放射标记的化合物。理论上，通式I化合物的任何位置都可被放射性核素替换，但优选对实施例中所示的卤素基、硝基进行取代，或对烷基进行标记。例如，当用 18F标记本发明的化合物时，可以用 18F标记化合物的任何位置，优选用 18F替换化合物中的硝基或氟原子。
本发明经放射标记的化合物及其制备所需的前体化合物通常可以通过常规方案，或实施例中公开的方案，或下述制备方法(通过用易得的同位素标记试剂替代非同位素标记试剂)而制备。已报道了诸多方法可将 11C、 15N、 18O、 18F或其他同位素标记到化合物中(Angew.Chem.Int.Ed.Miller,Philip W,2008,47,8998-9033；Peter J.H.Scott，2009,48,6001-6004；Chem.Rev.,Sean Preshlock,2016,116,719-766；Frederic Dollé,Fluorine-18chemistry for molecular imaging with positron emission tomography.Fluorine and Health：Molecular Imaging，Biomedical Materials and Pharmaceuticals(Tressaud，A.Haufe，G.),2008,pp.3-66，Elsevier)。经过放射性核素标记后的式I化合物可用作PET或SPECT的示踪探针进行活体中α-突触核蛋白积聚体的显像。
本发明还提供了前体化合物以用于制备放射核素标记的式I化合物。本领域技术人员可以根据本发明所示结构设计并合成该前体化合物。即，该前体化合物可以通过对市售化合物或对本发明化合物进行结构修饰而得到。
本发明的放射标记化合物可以通过不同的前体化合物制备。通常地，前体化合物的标记位置含有羟基或硝基、溴、碘、硼酸酯或其他易离去基团(如MsO-、TsO-等)，从而可以分别被 11C或 18F所标记。特别地，本发明式I化合物中所含的甲氧基可通过脱除甲基获得含有羟基的前体化合物，然后用 11C进行标记；或用已被 18F标记的溴代烷烃，如 18F-CH 2CH 2-Br进行氧烷基化反应，生成 18F-CH 2CH 2-O-取代产物，实现放射标记。同样地，前体化合物中也可以含有溴、碘、硼酸酯或TsO-、MsO-，这些基团按已知的常规方法可被 18F替换。例如，可用于制备放射示踪探针的化合物包括I-5(I-4和I-6的前体)，I-8(I-7和I-9的前体)，I-11(I-10和I-12的前体)，I-14(I-13和I-15的前体)等。在合成如I-6、I-9、I-12、I-15等化合物时，通常优先将前体化合物中需标记的位置转变成含易离去的TsO-、MsO-等基团。
通常，用于标记的核素由回旋加速器产生，本领域熟练的技术人员可以根据所要制造的核素来选择相应方法和仪器。使用这些放射性核素进行化合物标记的方法在本领域是已知的，主要包括化学合成法、同位素交换法和生物合成法。放射标记的本发明化合物可以局部地或者全身性地给予患者，经过与α-突触核蛋白结合和解离的充分时间后，通过PET、SPECT即可对检测部位进行可视化成像。给药途径可采用皮下、腹腔、静脉、动脉或脊髓液内的注射或输液或经口服，并充分关注患者的暴露剂量，具体使用方式取决于疾病类型、所使用的核素、所使用的化合物、患者状况、检测部位等因素。
本发明还提供用于成像诊断α-突触核蛋白积聚性疾病的组合物，其包含本发明的化合物、其在医药上可接受的盐、或其溶剂化物及医药上可接受的载体。优选组合物中的本发明 化合物已被标记，其中使用放射性核素(尤其是正电子放射性核素 11C、 13N、 15O、 18F等)进行标记对于体内成像诊断是优选的。根据其用途，优选本发明化合物或其组合物的形态是一种允许用于注射的形态。因此，医药上可接受的载体优选为液体，包括(但不限于)含水溶剂(如磷酸钾缓冲剂、盐水、林格氏溶液和蒸馏水)或无水溶剂(例如聚乙二醇、植物油、乙醇、甘油、二甲基亚砜和丙二醇)。可以适当选择载体和本发明化合物的配制比例，其取决于作用的部位、检测手段等。此外，本发明组合物可以包含常用的抗微生物剂(如抗菌素等)、局部麻醉剂(如盐酸普鲁卡因、盐酸待布卡因等)、缓冲液(如三盐酸缓冲液、HEPES缓冲液等)、渗透压调节剂(如葡萄糖、山梨糖醇、氯化钠等)等。
本发明化合物可以是标记的或未被标记的。当未被标记时，可以在使用前通过以上描述的常用方法对本发明化合物进行标记。
本发明化合物具有与α-突触核蛋白高度特异性结合的能力，因此可通过标记或未标记的本发明化合物，用于在体外对α-突触核蛋白的染色和定量。例如，由于本发明化合物具有自发荧光特性，因此可被直接用于染色标本中的α-突触核蛋白并通过激光共聚焦或荧光显微镜观察，或用于样本中α-突触核蛋白的比色定量；或经放射标记后使用闪烁计数器用于α-突触核蛋白的定量。共核蛋白病如帕金森病、路易体痴呆症、多系统萎缩等的早期病理基础都是形成路易体，其主要成分是异常积聚的α-突触核蛋白，通过对路易体的检测可以提供这些疾病的早期发病信息。由于本发明化合物能清晰染色路易体和路易神经突，因此可用于研究相关病理机制及患者死亡前后的诊断。使用本发明化合物对大脑切片进行染色可以通过常用方法来进行。如上所述，本发明化合物，即通式I所示的化合物或盐或其溶剂化物可以用作α-突触核蛋白积聚体的显像探针，优选使用经放射性核素标记的显像探针。
因此，本发明提供了：
用作显像α-突触核蛋白积聚体的示踪探针的通式I化合物、或其医药上可接受的盐或其溶剂化物；
用作成像诊断α-突触核蛋白积聚性疾病的光学及放射性示踪探针，特别是使用正电子放射性核素标记的显像示踪探针；
用作制备放射性同位素标记的式I化合物的前体化合物；
用作成像诊断α-突触核蛋白积聚性疾病的组合物，其包含通式I的化合物、或其医药上可接受的盐或其溶剂化物，及医药上可接受的载体；
通式I的化合物、其医药上可接受的盐或其溶剂化物用于诊断α-突触核蛋白积聚性疾病的用途；
使用通式I的化合物、其医药上可接受的盐或其溶剂化物在生产用于诊断α-突触核蛋白积聚性疾病的组合物中的用途。
此外，本发明还提供了：
用于例如大脑样本中的α-突触核蛋白聚集体、患者大脑中的路易体和路易神经突的检测/染色方法，该方法可用于提供α-突触核蛋白积聚性疾病的早期诊断和进展评估信息；
用于对脑内α-突触核蛋白的积聚进行定量或判定的方法；用于α-突触核蛋白积聚性疾病的预防和/或治疗药物的筛选方法；
以上所述方法均包含使用通式I的化合物、或其医药上可接受的盐或其溶剂化物，及医药上可接受的载体。
以下，针对式I化合物的取代基进行解释,进而对通式I化合物的盐、溶剂化物和衍生物、以及标记方法进行说明。
【定义】
除非另有指明，本发明的各种术语的含义和范围按如下定义进行说明和限定。
术语“式I的化合物”、“式I化合物”、“本发明的化合物”或“本发明化合物”是指 选自式I所限定的一类化合物的任意化合物，包括其立体异构体、顺反异构体、互变异构体、溶剂化物和盐(例如药用盐)。
除非另有指明，“或”或“和”的使用意指“和/或”。
当指示取代基的数目时，术语“一个或多个”意指从一个取代基到最大的化学上可能的取代数，即由取代基替代一个氢至替代所有氢。
术语“取代基”是指替代母体分子上的氢原子的原子或原子团。
术语“卤素”或“卤”是指氟(-F)、氯(-Cl)、溴(-Br)、及碘(-I)。
术语“TsO-”是指
Figure PCTCN2022137518-appb-000005
“MsO-”是指
Figure PCTCN2022137518-appb-000006
术语“C 1-4烷氧基”表示式-O-R’的基团，其中R’是指包含1至4个碳原子的一价直链或支链的饱和烷基。其实例包括甲氧基。
术语“卤代的C 1-4烷氧基”表示这样的烷氧基，其中所述烷氧基的一个或多个氢原子已被相同或不同的卤素原子(特别是氟原子)替代。其实例包括1-氟代乙氧基。
术语“C 1-3烷基”表示1至3个碳原子的一价直链或支链饱和烃基。其实例包括甲基。
术语“5～6元芳杂环”表示5或6个环原子的芳族单杂环，其包含1、2、3或4个选自N、O和S的杂原子，其余的环原子是碳。其实例包括噻吩环。
术语“芳族”表示例如在文献(特别是IUPAC-化学术语目录第2版，A.D.McNaught&A.Wilkinson.Blackwell Scientific Publications，Oxford(1997))中限定的芳香性的常规概念。
术语“在医药上可接受的盐”是指对哺乳动物、尤其是对人体无害的盐。可以使用包含无机酸或无机碱，或者包含有机酸或有机碱的、无毒性的酸或碱来形成在医药上可接受的盐。在医药上可接受的盐包括例如用铝、钙、锂、镁、钾、钠及锌等形成的金属盐；或用赖氨酸、N，N’-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺、甲葡胺(即N-甲基葡糖胺)及普鲁卡因等形成的有机盐等。另外，在医药上可接受的盐包含酸加成盐及碱加成盐。
术语“在医药上可接受的载体”是指生理盐水溶液；液态或固态的填充剂、稀释剂、溶剂、或封包材料等在医药上可接受的材料、组合物、或赋形剂。在医药上可接受的载体包括但不限于：水、食盐水、生理盐水或磷酸缓冲食盐水(PBS)、氯化钠注射液、林格氏注射液、葡萄糖注射液、无菌水注射液、葡萄糖、及乳酸林格氏注射液等。
术语“溶剂化物”是指，1个或多个溶剂分子与化合物缔合而形成的含溶剂化合物。例如可包含一溶剂化物、二溶剂化物、三溶剂化物、及四溶剂化物。另外，溶剂化物也包括水合物。
术语“水合物”是指，含有被非共价性分子间力所束缚的水的化合物或其盐，所含水的量可以是化学计量或非化学计量。例如包含一水合物、二水合物、三水合物以及四水合物等。
【α-突触核蛋白聚集体的示踪探针】
本发明提供的α-突触核蛋白聚集体的示踪探针(以下，也记作示踪探针)，即下式I所示的化合物、其在医药上可接受的盐、或其溶剂化物。
另外，下式I所示的化合物具有自发荧光。其中，化合物的1个或多个原子可以是该原子的放射性同位素。因此，本发明的化合物可作为小分子示踪探针用于α-突触核蛋白聚集体的光学成像，或经放射标记后的PET、SPECT成像。
Figure PCTCN2022137518-appb-000007
其中，
R 1为5～6元芳杂基，优选地取为吡啶基；
R 2选自卤素基、硝基、羟基、C 1-4烷氧基、卤代的C 1-4烷氧基，所述的卤素原子选自氟、氯、溴或碘；
R 3、R 4各自独立地选自氢，C 1-3烷基，优选地取自甲基；
环A选自苯环、5～6元芳杂环，优选地取自苯环、噻唑环。
其中，式I化合物的1个或1个以上原子是该原子的放射性同位素，该放射性同位素优选取自 11C、 13N、 15O、 18F、 76Br、 123I、 125I、 131I。
作为式I所示的化合物的具体例子，例如可举出以下的化合物：
Figure PCTCN2022137518-appb-000008
上述具体的化合物结构式中所示的*标记的原子(结构式中若有2个*标记，则指其中任意1个或2个)可以是该原子的放射性同位素，例如 11C或 18F。优选地，上述具体化合物中的F是放射性同位素 18F；优选地，与芳基连接的甲氧基或二甲氨基的碳原子是放射性同位素 11C。
本说明书中，( 18F)I-15等名称的含义是指：编号为I-15等的结构式中的具有*标记的原子是 18F；同理，( 11C)I-15等名称的含义是指：编号为I-15等的结构式中的具有*标记的原子是 11C。
【α-突触核蛋白聚集体的光学成像用组合物】
本发明的α-突触核蛋白聚集体的光学成像用组合物(以下也记作光学成像用组合物)包含上述式I化合物，其在药学上可接受的盐、或其溶剂化物。该光学成像包括试管内成像、生物体外成像、及生物体内成像。所述光学成像方法包括但不限于荧光显微镜测定法、多 光子成像法、双光子成像法、近红外荧光成像法。
【α-突触核蛋白聚集体的放射成像用组合物】
本发明的α-突触核蛋白聚集体的放射成像用组合物(以下也记作放射成像用组合物)包含经放射标记后的式I化合物，其在药学上可接受的盐、或其溶剂化物。该放射成像包括试管内成像、生物体外成像、及生物体内成像。所述放射成像方法包括但不限于PET、SPECT、放射自显影法(autoradiography)。
上述光学成像用组合物和放射成像用组合物均可包含于前述医药上可接受的载体中。其中所含的式I化合物、其在医药上可接受的盐、或其溶剂化物、以及在医药上可接受的载体的含量并无特别限定，可根据：所使用的化合物；被给予的哺乳动物的年龄、体重、健康状态、性別及餐食内容；给予的次数和途径；治疗期；同时使用的其他药剂等因素进行调整。
【α-突触核蛋白聚集体相关疾病的诊断药、或所述疾病的治疗或预防上的伴随诊断药】
本发明所述α-突触核蛋白聚集体相关疾病的诊断药、或所述疾病的治疗或预防上的伴随诊断药(以下也称为伴随诊断药)包含本发明的化合物。治疗上的伴随诊断药是指：在判明了所述疾病的情况下，用于判断是否有望实施治疗的诊断药。另外，预防上的伴随诊断药是指：在判明了所述疾病的前兆症状的情况下，用于预测今后的发病或者用于判断是否有望实施预防性发病抑制的诊断药。
将使用上述诊断药或伴随诊断药获得的受试者体内(如脑)α-突触核蛋白聚集体的量及/或分布量的相关数据，与预先已获知的上述疾病与α-突触核蛋白聚集体的量及/或分布量之间的相关性进行对照，则能够对受试者进行上述疾病的相关诊断(具体而言，如是否罹患有上述疾病、危重度、发作可能性等)；或了解受试者的上述疾病状态，基于此来制定上述疾病的预防/治疗计划(预防性给予/治疗药的种类及其组合、用量、用法等)。
【光学成像方法】
本发明所述的光学成像方法包含以下步骤，以下用检测脑中α-突触核蛋白聚集体的方法进行示例说明，检测其他部位时方法类似。
向受试生物体给予有效量的本发明示踪探针，到达生物体脑的示踪探针会与脑内的α-突触核蛋白聚集体结合。然后从脑外照射用于激发示踪探针的第1波长的光，并检测从脑内示踪探针发出的第2波长的光(例如荧光)，从而实现对α-突触核蛋白聚集体的光学成像(图像化)。其中，所述示踪探针包含式I所示的化合物、或其在医药上可接受的盐、或其溶剂化物。
【放射成像方法】
本发明所述的放射成像方法包含以下步骤，以下用检测脑中α-突触核蛋白聚集体的方法进行示例说明，检测其他部位时方法类似。
向受试生物体给予有效量的经放射标记的本发明示踪探针，到达生物体脑的示踪探针会与脑内的α-突触核蛋白聚集体结合。然后检测从该脑内的示踪探针发出的放射线，从而实现对α-突触核蛋白聚集体的放射成像(图像化)。其中，所述示踪探针包含式I所示的化合物、或其在医药上可接受的盐、或其溶剂化物，其中式I化合物的1个或1个以上原子是该原子的放射性同位素。
上述光学成像和放射成像受试生物体包括哺乳动物，例如人类、大鼠、小鼠、兔、豚鼠、仓鼠、猴、狗、貂、或小型猪等。优选地，哺乳动物是人类。所述示踪探针的给予方法无特别限定，可经口、静脉或腹腔给予。优选静脉或腹腔注射，最优选静脉注射。
【对脑内α-突触核蛋白的积聚进行定量或判定的方法】
通过上述成像方法，计算对受试生物体内(如脑内)所检测出的光或放射线的量及/或分布相比于其它正常哺乳动物的差值，则可对体内(如脑内)α-突触核蛋白的积聚进行定 量，并判断体内(如脑内)是否存在α-突触核蛋白聚集体的积聚。
【用于预防或治疗α-突触核蛋白积聚相关疾病的治疗或预防药物的筛选方法】
基于使用以上【光学成像方法】或【放射成像方法】中所述成像方法，检测受试生物体在给予了筛选药物前、后所发出的光或放射线，根据其强度及/或分布的差异判断α-突触核蛋白积聚的变化，以此筛选治疗或预防药物。例如，给予筛选药物后，如果来自示踪探针的光(如荧光)或放射线的量(强度)比给予筛选药物前减少，则该筛选药物可能用作该疾病或症状的治疗或预防用药物。进一步地，将来自所检测的受试生物体的光或放射线的量及/或分布与其它正常的哺乳动物进行比较，如果给予筛选药物后的结果比给予前更接近正常的哺乳动物，则该筛选药物可能用作该疾病或症状的治疗或预防用药物。
受试生物体种类及给予方法与以上【光学成像方法】及【放射成像方法】中所述相同。
本发明的化合物可以由已知的材料(例如市售的材料)通过公知的方法合成。本领域熟练的技术人员可以根据所需要的本发明的化合物适当选择原材料和合成方法。以下结合实施例进一步描述本发明，应理解，这些实施例仅用于说明本发明而不用于限制本发明的保护范围。下列实施例中未注明具体条件的实验方法，通常采用常规条件或按照制造厂商所建议的条件。本发明的已知的起始原料可以采用或按照本领域已知的方法制备，或购自于市售品。化合物的结构是通过核磁共振谱(NMR)和/或质谱来确定的。
实施例1：化合物I-1的制备，如下所示：
Figure PCTCN2022137518-appb-000009
步骤a：制备中间体b-1
将1.26g(10mmol)4-氟-邻苯二胺(a-1)溶于10ml无水乙醇中，加入2.32g(20mmol)丙酮酸乙酯,室温反应4h。反应结束后蒸干溶剂，甲醇重结晶，得到产物为白色固体，产率86％。ESI-MS(positive)：179.0(M+1) +。
步骤b：制备中间体c-1
将1.78g(10mmol)中间体b-1和1.49g(10mmol)4-二甲氨基苯甲醛溶于5ml冰醋酸中，加入催化量浓硫酸，氮气保护，加热回流反应8小时。反应结束后将反应液倒入冰水中，EA萃取3遍，饱和食盐水洗涤有机相并用无水硫酸镁干燥，经硅胶柱层析(石油醚：乙酸乙酯＝6：1)纯化，得到产物为红色固体，产率65％。 1H NMR(400MHz,DMSO-d 6)δ12.20(s,1H),7.80(d,J＝15.7Hz,1H),7.60(d,J＝7.8Hz,1H),7.47-7.35(m,4H),7.18-7.03(m,3H),2.98(s,6H)。ESI-MS(positive)：310.1(M+1) +。
步骤c：制备化合物I-1
将0.31g(1mmol)化合物c-1溶于3mL DMF，加入0.28g(2mmol)碳酸钾和0.71g(2mmol)2-溴甲基吡啶，室温反应8h。结束后将反应液倒入水中，EA萃取3遍，无水硫酸镁干燥，经硅胶柱层析(石油醚：乙酸乙酯＝4：1)分离纯化，得到产物为砖红色固体，产率18％。 1H NMR(600MHz,CDCl 3-d)δ8.59(d,J＝5.3Hz,1H),8.08(d,J＝16.0Hz,1H),7.79(dd,J＝8.9,5.9Hz,1H),7.65-7.54(m,4H),7.25(s,1H),7.23-7.14(m,2H),7.04-6.96(m,1H),6.71(d,J＝8.7Hz,2H),5.58(s,2H),3.03(s,6H). 13C NMR(150MHz,CDCl 3-d)δ161.83(d,J＝249.5Hz),154.54,151.39(d,J＝3.4Hz),150.59,148.92,138.12,136.54,132.75(d,J＝11.6Hz),130.39(d,J＝10.2Hz),130.08,128.97,123.91,122.26,121.42,116.16,111.37,111.22,111.07,101.18,47.77,39.60。ESI-MS(positive)：401.2(M+1) +。
实施例2：化合物I-2的制备，其结构如下所示：
Figure PCTCN2022137518-appb-000010
其制备方法同化合物I-1，只是在步骤c中将2-溴甲基吡啶替换为3-溴甲基吡啶，获得砖红色固体，产率20％。 1H NMR(600MHz,CDCl 3-d)δ8.66(s,1H),8.56(d,J＝4.8Hz,1H),8.08(d,J＝16.0Hz,1H),7.82(dd,J＝8.9,5.9Hz,1H),7.62-7.49(m,4H),7.25(s,1H),7.08-6.97(m,1H),6.88(dd,J＝10.0,2.5Hz,1H),6.71(d,J＝8.4Hz,1H),5.48(s,2H),3.04(s,6H). 13C NMR(150MHz,CDCl 3-d)δ161.79(d,J＝250.0Hz),154.51,151.40,150.66,148.79,148.10,138.44,134.19,132.17(d,J＝11.2Hz),130.84(d,J＝10.0Hz),130.17,130.12,129.05,123.78,123.25,115.83,111.37,111.22,100.27,100.09,43.28,39.59。ESI-MS(positive)：401.2(M+1) +。
实施例3：化合物I-3的制备，其结构如下所示：
Figure PCTCN2022137518-appb-000011
其制备方法同化合物I-1，只是在步骤c中将2-溴甲基吡啶替换为4-溴甲基吡啶，获得砖红色固体，产率20％。 1H NMR(600MHz,CDCl 3-d)δ8.58(d,J＝6.2Hz,2H),7.83(dd,J＝8.9,5.9Hz,1H),7.59(d,J＝8.7Hz,2H),7.55(d,J＝16.0Hz,1H),7.15(d,J＝5.9Hz,2H),7.05-7.01(m,1H),6.75–6.69(m,3H),5.46(s,2H),3.04(s,6H). 13C NMR(150MHz,CDCl 3-d)δ161.77(d,J＝250.3Hz),154.40,151.38,150.69,149.85,143.31,138.57,132.13(d,J＝11.1Hz),130.84(d,J＝10.0Hz),130.08,129.07,123.74,120.97,115.79,111.46,111.36,111.31,100.31,100.13,44.66,39.58。ESI-MS(positive)：401.2(M+1) +。
实施例4：化合物I-4的制备，如下所示：
Figure PCTCN2022137518-appb-000012
步骤d：制备中间体b-2
其制备方法同化合物b-1，只是将4-氟-邻苯二胺(a-1)替换为4-甲氧基-邻苯二胺(a-2)。得灰色固体，产率81％。ESI-MS(positive)：191.0(M+1) +。
步骤e：制备中间体c-2
其制备方法同化合物c-1，只是将中间体b-1替换为中间体b-2，得红色固体，产率55％。 1H NMR(400MHz,DMSO-d 6)δ12.29(s,1H),7.86(d,J＝16.1Hz,1H),7.62(d,J＝8.9Hz,1H),7.51(d,J＝8.1Hz,2H),7.31(d,J＝16.3Hz,1H),6.89(d,J＝8.9Hz,1H),6.73(s,3H),3.81(s,3H),2.96(s,6H)。ESI-MS(positive)：322.1(M+1) +。
步骤f：制备化合物I-4
其制备方法同化合物I-1，只是将中间体c-1替换为反应物c-2，获得砖红色固体，产率17％。ESI-MS(positive)：413.2(M+1) +。
实施例5：化合物I-6的制备，如下所示：
Figure PCTCN2022137518-appb-000013
将0.40g化合物I-4溶于2mL三溴化硼溶液中，室温反应3小时，反应结束后蒸干溶剂得I-5。随后加入3mL N,N-二甲基甲酰胺，加入0.08g碳酸钾和0.25g 1-溴-2-氟乙烷，室温反应8小时。反应结束后加入20mL水，用乙酸乙酯萃取并用无水硫酸镁干燥，硅胶柱层析(乙酸乙酯：石油醚＝1:1)纯化，得淡黄色固体，产率9％。 1H NMR(600MHz,CDCl 3-d)δ8.59(d,J＝4.8Hz,2H),8.00(d,J＝16.4Hz,1H),7.83(d,J＝9.2Hz,1H),7.70-7.49(m,3H),7.12(d,J＝5.5Hz,2H),6.97(d,4.4Hz,1H),6.71(d,J＝8.4Hz,2H),6.54(d,J＝2.4Hz,1H),5.50(s,2H),4.70(d,J＝22.9Hz,2H),4.28(d,J＝16.7Hz,2H),3.03(s,6H)。ESI-MS(positive)：445.2(M+1) +。
实施例6：化合物I-9的制备，如下所示：
Figure PCTCN2022137518-appb-000014
I-7的制备方法同化合物I-4，只是将2-溴甲基吡啶替换为3-溴甲基吡啶。后续步骤的制备方法同I-6。获得砖红色固体，产率12％。 1H NMR(600MHz,CDCl 3-d)δ8.55(d,J＝5.1Hz,2H),8.02(d,J＝14.8Hz,1H),7.73-7.52(m,4H),7.02(d,-6.95(m,3H),6.75-6.66(m,3H),5.50(s,2H),4.70(d,J＝37.2Hz,2H),4.11(d,J＝30.5Hz,2H),3.00(s,6H)。ESI-MS(positive)：445.2(M+1) +。
实施例7：化合物I-12的制备，如下所示：
Figure PCTCN2022137518-appb-000015
I-10的制备方法同化合物I-4，只是将2-溴甲基吡啶替换为4-溴甲基吡啶。后续步骤的制备方法同I-6。获得砖红色固体，产率14％。 1H NMR(600MHz,CDCl 3-d)δ8.57(d,J＝5.2Hz,2H),8.04(d,J＝16.0Hz,1H),7.79(d,J＝8.8Hz,1H),7.69-7.51(m,3H),7.15(d,J＝5.1Hz,2H),6.91(dd,J＝8.9,2.4Hz,1H),6.71(d,J＝8.4Hz,2H),6.54(d,J＝2.4Hz,1H),5.48(s,2H),4.72(d,J＝47.4Hz,2H),4.18(d,J＝28.1Hz,2H),3.03(s,6H). 13C NMR(150MHz,CDCl 3-d)δ158.39,154.70,150.49,149.72,143.83,137.42,132.30,130.44,128.83,128.52,124.03,121.04,116.37,111.40,110.28,99.22,80.98(d,J＝171.7Hz),66.92(d,J＝20.4Hz), 44.47,39.60。ESI-MS(positive)：445.2(M+1) +。
实施例8：化合物I-15的制备，如下所示：
Figure PCTCN2022137518-appb-000016
其中I-13的制备方法同I-4,只是在步骤e中将4-二甲氨基苯甲醛替换为2-二甲氨基噻唑-5-甲醛，后续步骤同I-6制备方法。获得红色固体，产率21％。 1H NMR(600MHz,DMSO-d 6)δ8.02(dd,1H),7.57(s,1H),7.81-7.67(m,2H),7.39-7.27(m,2H),7.01-6.85(m,4H),5.61(s,2H),4.71(m 2H),4.26(m,2H),3.13(s,6H). 13C NMR(150MHz,DMSO-d 6)170.38,158.67,154.97,154.23,149.02,145.42,136.96,133.32,130.04,127.99,127.49,125.45,122.50,121.73,117.35,111.32,99.83,81.69(d,J＝166.9Hz),67.49,55.53,46.61.ESI-MS(positive)：451.2(M+1) +。
【放射性核素的标记】
可采用常规已知的方法进行各种放射性核素的标记。以下用( 18F)I-1，( 18F)I-15和( 11C)I-13的制备为例，分别说明标记 18F和 11C的方法，其他放射性示踪探针可按相同方法制备。
实施例9：放射性示踪探针( 18F)I-1的合成
如下图所示，多种不同的前体化合物均可进行放射性核素 18F的标记。以下通过三种前体化合物(含硝基的前体、含溴的前体、含硼酸酯的前体)的合成方法进行示例说明，但不限于此。
Figure PCTCN2022137518-appb-000017
按实施例1的方法，将4-氟-邻苯二胺分别替换为4-硝基-邻苯二胺和4-溴-邻苯二胺，分别制备含硝基的前体化合物I-1N和含溴的前体化合物I-1B。进一步地，含溴前体I-1B在钯催化下与频哪醇硼酸酯偶联制备活性更高的含硼酸酯的前体化合物I-1O。以上三种前体化合物都能够与放射性K 18F反应生成放射性示踪探针( 18F)I-1。
方法1：由含硼酸酯的前体化合物I-1O合成。 18F-由回旋加速器生产，然后经过QMA吸附，由1号瓶压出K 222/K 2CO 3洗脱液洗脱 18F离子至反应管中，在116℃及氮气流下蒸干。2号瓶溶液(2mL乙腈)注入反应管，在116℃及氮气流下共沸蒸干除水。反应管冷却60s。3 号瓶溶液(8mg前体化合物I-1O溶于1mL DMF)注入反应管，反应温度115℃，反应时间30min。冷却100s(≤40℃)。4号瓶溶液注入反应管(10mL注射用水)稀释，传至C-18柱富集，注射用水20mL，将C-18柱用2.5mL无水乙醇洗脱备用。用生理盐水稀释产物的乙醇溶液至乙醇含量低于10％。并用0.22μm滤膜过滤获得可用于注射的( 18F)I-1溶液。所得产物与非放射性化合物I-1进行HPLC图谱比对，两者保留时间一致，证明放射标记探针制备成功。
方法2：由含硝基的前体化合物I-1N合成。使( 18F)氟化物离子溶入到包含K 222(Kryptofix222)(7.5mg)及碳酸钾(2.77mg)的50％乙腈溶液(0.4mL)中，将该溶液引入到反应容器中之后，在氮气流下加热，使溶剂干燥固化。然后添加无水乙腈(0.1mL)共沸蒸馏，使反应容器内充分干燥。将溶有含硝基的前体化合物I-1N(1mg)的DMSO(300μL)溶液添加到反应容器中，在110℃下加热10分钟。冷却后，经HPLC分离纯化，获得( 18F)I-1纯品。
同理，含溴的前体化合物I-1B也可用上述方法2的类似条件进行 18F标记，合成( 18F)I-1。
实施例10：放射性示踪探针( 18F)I-15的合成
如下图所示，放射性示踪探针( 18F)I-15可用其前体化合物I-14与已被 18F标记的溴代烷烃 18F-CH 2CH 2-Br直接进行氧烷基化制备。或将I-14与1,2-双(甲苯磺酰氧基)乙烷反应生成含离去基TsO-的前体化合物I-15T；也可将I-14与环氧乙烷反应先生成含末端羟基的化合物I-15O，再与对甲基苯磺酰氯(TsCl)或甲烷磺酰氯(MsCl)等在碱性条件下反应，生成标记位点含易离去基团(如TsO-或MsO-)的前体化合物(如I-15T)；最后将I-15T与放射性K 18F反应生成放射性示踪探针( 18F)I-15。
Figure PCTCN2022137518-appb-000018
前体化合物I-15T的制备示例：0.16g化合物I-14溶于5mL N,N-二甲基甲酰胺，加入0.11g碳酸钾(2eq)和0.3g化合物1,2-双(甲苯磺酰氧基)乙烷(2eq)，室温搅拌过夜。反应结束后加入20mL水，乙酸乙酯萃取，无水硫酸镁干燥，粗品用硅胶柱层析(PE:EA＝1:1)，分离得目标产物。
由含TsO-基的前体化合物I-15T制备( 18F)I-15的示例如下。
将( 18F)氟化物离子溶入到包含K 222(Kryptofix 222)(7.5mg)及碳酸钾(2.77mg)的50％乙腈溶液(0.4mL)中，将该溶液引入到反应容器中之后，在氮气流下加热，使溶剂干燥固化。然后添加无水乙腈(0.1mL)共沸蒸馏，使反应容器内充分干燥。将溶有前体I-15T(1.0mg)的DMSO(300μL)溶液添加到反应容器中，在110℃下加热10分钟。冷却后经HPLC(C18柱)分离纯化获得( 18F)I-15。
实施例11：放射性示踪探针( 11C)I-13的合成，如下图所示，该合成需避光进行。室温下将碘( 11C)甲烷添加到溶有I-14(2mg)的二甲基亚砜(DMSO)(300μL)溶液中。将反应混合液在120℃下加热5分钟。反应容器冷却后，用HPLC纯化分离。将( 11C)I-13组分回收至含有乙醇(300μL)、25％抗坏血酸(100μL)及Tween80(75μL)的烧瓶中，减压蒸馏除去溶剂。 将残余物溶解在生理盐水(3mL，pH 7.4)中，获得作为注射溶液的( 11C)I-13。
Figure PCTCN2022137518-appb-000019
【对α-突触核蛋白聚集体的结合力测试】
通过以下所述的荧光法测定本发明化合物对人源α-突触核蛋白聚集体的结合活性。
(1)α-突触核蛋白单体制备
取1μL测序正确的载有α-突触核蛋白表达序列的氨苄青霉素抗性质粒与100μL BL21(DE3)感受态细胞混合均匀，冰浴冷却，加入600μL LB培养液，置于37℃，220rpm摇床培养90min。将培养好的菌液150μL加至有氨苄培养基的灭菌培养皿涂布均匀，挑取阳性克隆菌落加入配置好的氨苄培养基中，37℃培养箱中培养。将培养好的阳性克隆菌液倾入1L的2×YT培养基中，在220rpm摇床中以37℃培养至OD 600为0.6时降温至18℃，每瓶培养基加入500mM IPTG 1ml诱导培养16小时。
离心收集菌体，超声破碎后高速离心30min，收集上清液，经Ni-NTA亲和柱层析去除DNA和杂蛋白，再通过分子排阻层析纯化得到α-突触核蛋白单体，以SDS-PAGE不连续电泳验证纯度。
(2)α-突触核蛋白聚集体制备
将α-突触核蛋白单体配置成含1×PBS的Buffer溶液，其中蛋白终浓度100μM(约5mg/mL)，置于37℃下1000rpm摇床中孵育7天获得α-突触核蛋白聚集体。初始蛋白单体浓度和终浓度均以BCA法精确测定。
制备的α-突触核蛋白聚集体也称为预制纤维(preformed fibrils，PFFs)，用于本发明所述的蛋白亲和力测试、细胞模型的构建及测试。
(3)化合物结合活性测试
称取约1mg化合物，用DMSO配置成10mM母液，随后用PBS稀释成20μM，并进行7次梯度稀释(每次稀释三倍)；将30μL待测化合物加入384孔板，实验组加入30μLα-突触核蛋白聚集体(3μM)，对照组加入等量PBS，将384孔板于室温中震荡(50rpm)孵育1小时；随后将孔板取出，用酶标仪检测化合物的最大吸收、发射波长，并在该波长下检测荧光值。用实验组扣减对照组计算出分子不同浓度的荧光变化值，用GraphPad Prism的Saturation binding模块计算化合物对蛋白的结合力。
本发明式I化合物对α-突触核蛋白聚集体的结合活性通过以上方法测定，所得解离平衡常数K d结果如表1所示。
表1本发明部分式I化合物对人源α-突触核蛋白聚集体的结合活性(K d)
实施例化合物 K d(μM) 实施例化合物 K d(μM) 实施例化合物 K d(μM)
I-1 *** I-6 ** I-15 ***
I-2 * I-9 *    
I-3 * I-12 **    
*:1.0～0.5μM；**:0.5～0.2μM；***:0.2～0.1μM。
【细胞模型的免疫荧光成像】
SH-SY5Y细胞属于SK-N-SH细胞系，是人源神经母细胞瘤细胞的一种。该细胞可以表达多种神经元的重要蛋白，例如多巴能转运体、多巴胺羟化酶、酪氨酸羟化酶等，因此常被用于研究帕金森病的机制和药效评估。本发明将制备好的α-突触核蛋白聚集体(PFFs)与SH-SY5Y细胞共孵育，通过胞吞作用，12小时后α-突触核蛋白聚集体可被内吞至细胞内。然后将该模型细胞分别与α-突触核蛋白抗体和化合物进行孵育，经PBS洗涤后在显微镜下观察。具体操作如下。
将SH-SY5Y细胞培养于高糖DMEM培养基中(含有10％Gibco胎牛血清)，当复苏传代5次后，细胞状态趋于稳定，随后在培养基中加入PFFs，培养48h后进行荧光染色实验。吸干细胞培养液，用PBS清洗三次后，加入0.3％Triton X-100孵育10min；PBS清洗后加入10％山羊血清封闭1h；PBS清洗后加入一抗(1:1000,610786,BD Biosciences)在4℃孵育过夜；PBS清洗后加入二抗(1:1000,goat-anti rabbit Alex Fluor 594and goat-anti-mouse Alex Fluor 488,Invitrogen)在室温孵育2h；最后加入本发明化合物室温孵育1h，PBS清洗后封片并用激光共聚焦显微镜拍照。
结果如图1所示，表明所测试的式I化合物均能对SH-SY5Y细胞模型中的α-突触核蛋白聚集体进行良好结合，尤其化合物I-6、I-12、I-15同时表现出了优秀的靶点结合活性和特异性，基本未发生非特异性结合。
【病人脑的光学成像】
路易小体痴呆患者(DLB)脑片的染色及成像
路易小体痴呆病人脑片取自一位75岁男性逝者的脑杏仁核组织，生前患有2期路易小体痴呆症。对富含α-突触核蛋白病变的杏仁核组织进行冰冻切片，切片厚度为20μm。
将待测化合物I-15用含50％EtOH的PBS溶液稀释成30μM，室温下与获得的新鲜冷冻脑切片孵育30分钟，随后用50％乙醇溶液洗涤5分钟，再用超纯水洗涤2次，每次3分钟。使用封埋剂(VECTASHIELD H-1000，Vector Laboratories)封埋切片后，通过荧光显微镜拍照，获得切片上的病变积聚区域的图像。使用分析软件(Image J)对病变区域及病变非形成区域(背景)的荧光辉度进行定量，以评估结合选择性。
附图2的荧光图像结果显示化合物I-15能清晰地染色路易体痴呆病人脑片中的路易体和路易神经突，表明其能与病人脑中的α-突触核蛋白病变发生强结合。
阿尔茨海默患者(AD)脑片的染色及成像
阿尔茨海默病人脑片取自一位3期患者逝后的脑颞上回组织。将脱蜡后的脑组织在10％中性缓冲福尔马林液中固定，石蜡包埋后切片，切片厚度为6μm。检测方法同上述对路易小体痴呆患者(DLB)脑片的染色方法一样。荧光图像结果如附图3所示，化合物I-15也能探测到AD病人脑片中的Aβ原始斑块、Aβ致密核心斑块、Tau神经纤维缠结，不与Tau神经纤维丝结合。很明显地，在AD病人脑片中，化合物的染色信号远弱于对DLB病人脑片的染色信号，表明I-15对Aβ和Tau病理组织的结合都很弱。
由附图2、图3结果可知，化合物I-15对α-突触核蛋白病理组织的结合明显强于对Aβ、Tau病理组织的结合，表明其对α-突触核蛋白聚集体具有非常好的选择性。
【血脑屏障渗透性测试】
根据下列方法，对大鼠尾静脉注射本发明化合物以测定其体内的血脑屏障渗透性。
将待测化合物溶解于DMSO中，加入蓖麻油和PBS进行稀释(DMSO：蓖麻油：PBS＝1：1：8)；对SD大鼠进行称重，以5mg/kg进行尾静脉给药；用异氟烷麻醉，给药20min后取血500μL。随后用200mL PBS进行心脏灌流，待器官褪色后停止灌流，取出脑组织，用PBS冲洗表面。
取出的血液用9000rpm离心5min，取200μL上清液，加入800μL甲醇，14000rpm离心10min，取上清液过0.22μm滤膜，保存于-80℃备用。
取约0.5g脑组织，加入2mL PBS和2mL甲醇进行组织匀浆，取出1mL匀浆液加入2mL甲醇，14000rpm离心10min，取1mL上清液过0.22μm滤膜并保存于-80℃备用。对上述血液样本和脑匀浆上清液样本分别用LC-MS/MS检测其中的化合物浓度。
当脑/血比值＜0.1，0.1～0.3或＞0.3分别表示化合物透过血脑屏障程度为难、适中或良好。测试结果表明本发明化合物I-6、I-12、I-15的脑/血比接近1.0或大于1.0，证明它们都具有很好的血脑屏障渗透能力。由于本发明化合物结构相似，且clogP值多在1.0～3.0之间，因此可以预测本发明其它化合物也应具有可接受的血脑屏障渗透能力。
工业实用性
本发明的能够结合/染色α-突触核蛋白积聚体的探针化合物及其组合物对于当前十分重要的医疗难点之一的帕金森病等疑难病症的早期发现、医疗和预防都极为重要，并且具有用于医疗领域的极高的可能性。本发明化合物可以作为显像示踪剂用于显像α-突触核蛋白的积聚，从而能对多种神经退行性疾病，例如帕金森病(PD)、帕金森病性失智症(PDD)、路易体痴呆症(DLB)、多系统萎缩(MSA)等提供早期诊断和疾病进展的信息。

Claims (10)

  1. 通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其用作诊断α-突触核蛋白积聚性疾病的示踪探针，
    Figure PCTCN2022137518-appb-100001
    通式I中，
    R 1为5～6元芳杂基；
    R 2选自卤素基、硝基、羟基、C 1-4烷氧基、卤代的C 1-4烷氧基，其中，所述的卤素原子选自氟、氯、溴或碘；
    R 3、R 4各自独立地选自氢，C 1-3烷基；
    环A选自苯环、5～6元芳杂环。
  2. 根据权利要求1所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其特征在于，所述R 1为吡啶基。
  3. 根据权利要求1所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其特征在于，所述R 3、R 4为甲基。
  4. 根据权利要求1所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其特征在于，所述环A为苯环或噻唑环。
  5. 根据权利要求1-4中任意一项所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其特征在于，所述化合物的1个或1个以上原子是该原子的放射性同位素，其中，所述的放射性同位素选自 11C、 13N、 15O、 18F、 76Br、 123I、 125I、 131I。
  6. 根据权利要求5所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，其特征在于，所述化合物选自以下结构：
    Figure PCTCN2022137518-appb-100002
    其中，具有*的原子中至少有一个是该原子的放射性同位素。
  7. 下式所示的前体化合物，其特征在于，所述前体化合物用于合成权利要求6所述的化合物，
    Figure PCTCN2022137518-appb-100003
    其中，R 5为吡啶基；R 6独立地取自羟基、氟、溴、碘、硝基、硼酸酯基、TsO-(CH 2)m-O-、MsO-(CH 2)m-O-，其中，m为2～4的整数。
  8. α-突触核蛋白聚集体的光学显像用组合物，其特征在于，包含权利要求1～4中所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，及医药上可接受的载体。
  9. α-突触核蛋白聚集体的放射显像用组合物，其特征在于，包含权利要求5～6所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物，及医药上可接受的载体。
  10. 权利要求1所述的通式I所示的化合物、其在医药上可接受的盐、或其溶剂化物的用途，其特征在于，所述化合物、其在医药上可接受的盐、或其溶剂化物能与α-突触核蛋白聚集体结合，用作诊断α-突触核蛋白积聚性疾病的显像示踪探针。
PCT/CN2022/137518 2021-12-09 2022-12-08 结合α-突触核蛋白聚集体的小分子探针及其用途 WO2023104148A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111498028.9A CN116251199A (zh) 2021-12-09 2021-12-09 结合α-突触核蛋白聚集体的小分子探针及其用途
CN202111498028.9 2021-12-09

Publications (1)

Publication Number Publication Date
WO2023104148A1 true WO2023104148A1 (zh) 2023-06-15

Family

ID=86679739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/137518 WO2023104148A1 (zh) 2021-12-09 2022-12-08 结合α-突触核蛋白聚集体的小分子探针及其用途

Country Status (2)

Country Link
CN (1) CN116251199A (zh)
WO (1) WO2023104148A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112110829A (zh) * 2019-06-19 2020-12-22 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途
CN112645891A (zh) * 2019-10-10 2021-04-13 复旦大学 与α-突触核蛋白聚集体结合的小分子化合物、其制备方法及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112110829A (zh) * 2019-06-19 2020-12-22 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途
CN112645891A (zh) * 2019-10-10 2021-04-13 复旦大学 与α-突触核蛋白聚集体结合的小分子化合物、其制备方法及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, MINGMING ET AL.: "Advances in the Development of Imaging Probes and Aggregation Inhibitors for Alpha-synuclein", ACTA PHARMACOLOGICA SINICA, 4 October 2019 (2019-10-04), pages 483 - 498, XP037079648, DOI: 10.1038/s41401-019-0304-y *

Also Published As

Publication number Publication date
CN116251199A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
CA2419420C (en) Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2438032C (en) Benzothiazole derivative compounds, compositions and uses
JP4831421B2 (ja) 可溶性βーアミロイドの非侵襲的画像法のための組成物及び方法
US20070258887A1 (en) Compounds and amyloid probes thereof for therapeutic and imaging uses
JPWO2005016888A1 (ja) アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
TWI528977B (zh) New amyloid affinity products
EP2501696A2 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JPWO2007074786A1 (ja) コンフォーメーション病診断プローブ
JPWO2015060365A1 (ja) タウイメージングプローブ
JPWO2004054978A1 (ja) タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体
JP2007223952A (ja) アミロイドβ蛋白が蓄積する疾患の画像診断プローブ
Hostetler et al. [18F] Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey
CA2500358A1 (en) Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles
JP2004250411A (ja) アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
JP2000344684A (ja) ピロニンｂ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
Abrahamson et al. Development of a PET radioligand selective for cerebral amyloid angiopathy
WO2023104148A1 (zh) 结合α-突触核蛋白聚集体的小分子探针及其用途
JP2000344685A (ja) アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
WO2023109745A1 (zh) 用于α-突触核蛋白聚集体成像的小分子探针
WO2023098622A1 (zh) α-突触核蛋白聚集体的小分子结合配体、其制备方法及用途
WO2010125907A1 (ja) コンフォメーション病診断用組成物
JP2004067659A (ja) タウ蛋白蓄積性疾患の診断プローブとしてのベンゾイミダゾール環含有化合物
JP2004250407A (ja) アミロイド蓄積性疾患の診断プローブおよび治療用化合物
BR112018006969B1 (pt) Derivados de azetidina para formação de imagem de tau, seu intermediário, seu uso e seu processo de preparação, e composição
WO2014132919A1 (ja) 診断用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22903567

Country of ref document: EP

Kind code of ref document: A1